Inrebic for patients with intermediate-2 or high-risk primary or secondary myelofibrosis, approved by FDA
The FDA ( Food and Drug Administration ) has approved Inrebic ( Fedratinib ) for adults with intermediate-2 or high-risk primary or secondary ( post-polycythemia vera or post-essential thrombocythemia ) myelofibrosis ( MF ).
Efficacy was investigated in JAKARTA, a double-blind, randomized, placebo-controlled trial in 289 patients with intermediate-2 or high-risk myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis with splenomegaly.
Patients were randomized to receive either INREBIC 500 mg ( n=97 ), 400 mg ( n=96 ) or placebo ( n=96 ) once daily for at least 6 cycles.
The primary efficacy outcome was the proportion of patients achieving greater than or equal to 35% reduction from baseline in spleen volume at the end of cycle 6 measured by MRI or CT with a follow-up scan 4 weeks later.
Of the 96 patients treated with the recommended dose ( 400 mg ) of Fedratinib, 35 ( 37% ) have achieved a greater than or equal to 35% reduction in spleen volume, compared with 1 of 96 patients who received placebo ( p less than 0.0001 ).
The median duration of spleen response was 18.2 months for the Fedratinib 400 mg group.
In addition, 40% of patients who received 400 mg experienced a greater than or equal to 50% reduction in myelofibrosis-related symptoms, whereas only 9% of patients receiving placebo experienced a decline in these symptoms.
The prescribing information for Fedratinib includes a Boxed Warning to advise health care professionals and patients about the risk of serious and fatal encephalopathy, including Wernicke’s encephalopathy.
Health care professionals are advised to assess thiamine levels in all patients prior to starting Fedratinib, periodically during treatment, and as clinically indicated.
If encephalopathy is suspected, Fedratinib should be immediately discontinued and parenteral thiamine initiated.
The most common adverse reactions ( greater than or equal to 20% ) in patients who received Fedratinib were diarrhea, nausea, anemia, and vomiting.
The recommended Fedratinib dose is 400 mg orally once daily with or without food for patients with a baseline platelet count of greater than or equal to 50 x 109/L.
It is necessary to reduce dose for patients taking strong CYP3A inhibitors or for patients with severe renal impairment. ( Xagena )
Source: FDA, 2019
Rinvoq, an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Rinvoq ( Upadacitinib ), a 15 mg, once-daily oral...
The FDA ( Food and Drug Administration ) has granted accelerated approval to Xpovio ( Selinexor ) in combination with...
Relapsed and refractory multiple myeloma: European Commission has approved Empliciti plus Pomalidomide and low-dose Dexamethasone
The European Commission ( EC ) has approved Empliciti ( Elotuzumab ) plus Pomalidomide and low-dose Dexamethasone ( EPd )...
Xospata as a monotherapy for patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation, approved in European Union
The European Commission ( EC ) has approved the oral once-daily therapy Xospata ( Gilteritinib ) as a monotherapy for...
Long-term efficacy and safety of first-line Ibrutinib treatment for patients with chronic lymphocytic leukemia / small lymphocytic lymphoma: 5 years of follow-up from RESONATE-2 trial
RESONATE-2 is a phase 3 study of first-line Ibrutinib ( Imbruvica ) versus Chlorambucil in chronic lymphocytic leukemia ( CLL...
FDA: Reblozyl for the treatment of anemia in adult patients with beta-thalassemia who require regular RBC transfusions
The FDA ( U.S. Food and Drug Administration ) has granted approval to Reblozyl ( Luspatercept–aamt; Luspatercept ) for the...
The FDA ( Food and Drug Administration ) has granted accelerated approval to Polatuzumab vedotin-piiq ( Polivy; Polatuzumab vedotin ),...
DRIVE PK Study in patients with pyruvate kinase deficiency: data for Mitapivat from Core and Extension phases
New data from the core and extension phases of the DRIVE PK phase 2 study of Mitapivat ( AG-348 )...
Keytruda as first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma: two new regimens approved by European Commission
The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...